hrp0089p2-p398 | Thyroid P2 | ESPE2018

Diagnosis and Clinical Course of Amiodarone Induced Hyperthyroidism in Three Adolescent Patients

Gesing Julia , Hoppmann Julia , Gebauer Roman , Pfaffle Roland , Bertsche Astrid , Kiess Wieland

Amiodarone induced hyperthyroidism is a known side effect of amiodarone treatment. In the pediatric population long-term amiodarone treatment is rarely indicated because of its severe side effects including thyroid function impairment and therefore treatment is restricted to therapy resistant arrhythmias. In the literature scarce data is available on management and therapy of amiodarone induced thyroid dysfunction at a young age. We present three adolescent patients developin...

hrp0097p2-91 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Peripheral Precocious Puberty due to Exogenous Estradiol in a 3-Year-Old Girl: A Case Report

Bruun Rasmussen Astrid , Højgaard Astrid , Nymark Hansen Rikke , Rønholt Christensen Ann-Margrethe

Introduction: Transdermal estrogen replacement therapy in girls with hypogonadism is well known for induction of the puberty. Sexual development due to exogenous exposure for sex steroids in food, environment or medication is known, but is rare and sparsely reported. We present a case of peripheral precocious puberty in a 3-year-old girl due to inadvertent exposure to an estradiol gel used by her father as gender affirming hormone therapy (GAHT).<p class="...

hrp0092p1-246 | Multisystem Endocrine Disorders | ESPE2019

Knowledge of the Natural History of Paediatric MEN1 is Required to Inform Decision Making for Predictive Testing in Childhood

Park Julie , Collingwood Catherine , Weber Astrid , Blair Joanne

Background: Multiple Endocrine Neoplasia type 1 (MEN1) is a dominantly inherited syndrome characterised by parathyroid hyperplasia, pancreatic neuroendocrine tumours (PNET) and pituitary adenomas, although >20 tumours are described. Clinical guidelines1 recommend annual biochemical surveillance and abdominal imaging from <10yrs and pituitary imaging every 3yrs. Age at start of surveillance is derived from the youngest reported patient with a...